Kiora Pharmaceuticals (KPRX) Fundamental Analysis: Revenue, Earnings & Valuation

3.60 / 10

Netural

Fundamental assessment: 3.6/10 points to weak condition. Positive attributes: Interest coverage ratio (EBIT / Interest expense) (%) and Revenue-MV, with caution warranted for Income tax / Total profit (%) and Quick ratio. Concluding perspective: selective.

Analysis Checks(5/10)

Revenue-MV

Value-0.18

Score3/3

Weight51.06%

1M Return8.82%

Total operating revenue (YoY growth rate %)

Value-100.00

Score2/3

Weight1.53%

1M Return0.35%

Quick ratio

Value2.34

Score1/3

Weight-3.76%

1M Return-0.93%

PB-ROE

Value-0.81

Score1/3

Weight27.79%

1M Return6.08%

Income tax / Total profit (%)

Value10.58

Score1/3

Weight-5.08%

1M Return-1.22%

Long-term debt to working capital ratio (%)

Value0.25

Score2/3

Weight2.45%

1M Return0.56%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight-3.21%

1M Return-0.77%

Cost of sales ratio (%)

Value71.87

Score2/3

Weight-2.43%

1M Return-0.61%

Asset-MV

Value-0.72

Score1/3

Weight35.81%

1M Return6.94%

Current ratio

Value5.99

Score1/3

Weight-4.16%

1M Return-1.01%

Is KPRX fundamentally strong?

KPRX scores 3.60/10 on fundamentals and holds a Fair valuation at present. Backed by its -51.74% ROE, 0.00% net margin, -0.89 P/E ratio, 0.60 P/B ratio, and -379.57% earnings growth, these metrics solidify its Netural investment rating.